tors a re c haracterized by hi g h interpatie nt vari ability. Thi s variability ca n be explai ned by many factors, in cl udin g drug-d rug interactions, impaired abso rpti on caused by e ithe r presence or absence of food, a nd patient-re lated factors. Gender may be one of these factors, as it is well known th at large diffe re nces can ex ist in the way me n and women meta bo li ze drugs ( 1,2). So fa r, little attention has been pa id to the possibility of gende r being a re leva nt de termin ant of in terp at ie nt vari ab ility of HIVprotease inhibitor pharmacok in eti cs. For ex ampl e, the product monograp h of indin av ir (Crixiva n; M e rc k & Co., Ra hw ay, NJ, U .S.A.) me ntions onl y that no influe nce of gender has been noted o n indinav ir pharmaco kin e tics (3), desp ite data from prec lini ca l resea rc h indicating that indin av ir di s pla ys sexdependent pharmacokinetics (4). We have rev iewed indinavir plasma co ncentrations in HIV-infected wome n a nd co mpared them w ith indinav ir co ncentrat io ns in a co ntrol gro up of men.
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The Department of C lini ca l Pharmacy at the U ni versity Medical Centre N ijmegen is a national referra l center for therapeuti c drug mo nito1ing of indinavir in The Netherlands. From o ur database we selected a ll female patients who were us ing indin av ir. Other inform at io n collected in c luded age, body we ight, dose reg im e n, indicati o n for drug level mo nitorin g, a nd in dinavir pl as ma concentrati o n. Individua l plasma co nce ntrati ons of patients us ing 800 mg of indinav ir every 8 h we re co mpared with the tim e-adjusted plas ma co ncentrati on values in a population o f 14 HIV-infected patient ( 12 male, 2 fema le) from who m an 8-hour pharmacokinetic c urve was reco rded afte r observed intake. The ratio of the indi vidua l va lu e versus th e population va lue is call ed the inclin av ir concen trati o n ratio (C R). The pharmacokinetic pa ra mete rs of the popul ati on c urve (AUC, Cmax, Cm;,,) are comparable w ith literature d ata of 800 mg of inclinavir ( 19.1 mg/L per ho ur, 8.7 mg/L, a nd 0. 13 mg/L, respective ly (3)) . A co ntro l gro up of 94 men was chosen by ra ndom ly selecting inclin av ir plas ma sa mp les that were received at the sa me day of the sa mpl es from th e fema le group. Differe nces between wo me n and me n were tested fo r s ig nificance by Mann-Whitney U test o r the two-sa mpl e proportio n test.
A tota l of 380 sa mpl es fro m 220 fema le patie nts was a vailable fo r analysis. Out of thi s group , 227 sam pl es ca me from patients us ing 800 mg of inclinavir every 8 hours. The median CR of inclinavir in these sa mples was 1.1 8 (inte rquartile range: 0 .65-1. 89), with 58. 8% of the sa mpl es havin g an indinavir CR > 1.00. In the con trol gro up of 94 me n, 6 1 sa mpl es ca me from patients using indinav ir 800 mg every 8 hours. The median CR of inclinav ir in these sa mpl es was 0.96 (inte rquartil e range: 0.60-1.70) with 47.4% of the sa mples having an inclinav ir CR > l.00. The difference in the ind in avir CRs between me n and women is not significa nt (p = . l 9), sugges ting no diffe rence in in d in av ir pharmacokinetics between men a nd wo me n.
Ho wever, some additional co mments can be made. First, " intoxication" was noted as an indication for drug level monitoring in 17.4% of the women ve rsus 6 .6 % of th e men (p = .03). Second, a close reduction of inclinavir to 600 o r 400 mg every 8 ho urs after a di agnos is of indin avir-relatcd s ide effects was app li ed in 9.7% of the fema le patients versus 1. 1 % of the mal e patients (p < .01 ). F in all y, the proportion of patients with an inclinavir CR >2.0 , which has been assoc iated with an in creased ri sk of urolog ic co mpl a in ts (5), was hi gher in women th an in me n (2 1.3 % vs. 13. 1 %, p = .15).
These data in d icate that wo men , as a gro up , have roug hl y simil ar pharmacokinetic para me te rs of indinav ir compared with men , whi ch is in agreeme nt w ith the produc t labe ling (3), but that a subgroup of I 0 % to 20% of the wo me n may have substa nti a ll y e levated indin avi r plas ma concentrations. Ge nderre lated d iffere nces in ph a rm acokine tics can be attributed to me tabo li c variations in cytochrome P450 e nzy mes, protein bind in g, and body we ig ht or co mpositi o n ( I ). Even thoug h the wome n in our data set had a lower medi an body weig ht th an the me n (63 vs. 75 kg) , no re lationship between low body we ight and increased indinavi r exposure was fo und.
Recently, sim ilar relationships be tween gender a nd pharmacokin eti cs were reported for verapam il , wh ich, like indi nav ir, is a cytochrome P450 a nd P-g lycoprote in substrate (6) . Elevated drug concentrati o ns resu lt in a hi gher risk fo r side effects . Several recent cohort studi es have confirmed thi s hi gher inc idence of side effects in wo me n versus me n (7, 8) . Our data sugges t that wome n who experi e nce indina vir-re lated toxicity may bene fit from dose red uctio n, under the g uid ance of th erapeutic drug mo nitoring . "A ntirctroviral therapy taken at time of res istance genotype determin ation. "Phenotypic res ults are ex pressed as RVA index determined fo r each drug te,tcd: RV A index< 4 indicates phenotypic sensi ti vity; RV A index between 4 and I 0 indicates low level of resistance; RV A index > I 0 indicates hi gh level of re, istance. csince the same genotypic pattern was observed in the HIV-I RNA and D A RT po! gene, the RVA indexes for plas ma HIV-I RNA and PBMC HIV-I DNA were considered similar. din italics are shown th e aminoacid s of consensus HIV-I RT seq uence of the HXB2 reference HI Y-1 strain. ' In bold are shown codons harboring mutated aminoacids by reference to the HXB2 H-1 strain . (-) represents aminoacid insertions. ND. not determined; RT, reverse tran scriptase; RTI, reverse transcriptase inhibitor; PI, protease inhibitor; RVA , recombinant virus reverse transcriptase inhibitor sensi ti vity assay; PBMC, peripheral blood mononuclear cell s; ABC, abacavi r; EFV , efav irenz; NVP, nev irapine; NFV, nelfinavi r; d4T, stavud ine; dell. diclanosi ne; 3TC, lami vudine.
